Antiviral treatments reduce severity of diabetes in Ljungan virus-infected CD-1 mice and delay onset in diabetes-prone BB rats

Rebecka Holmberg, William Klitz, Martin Blixt, Per Olof Berggren, Lisa Juntti-Berggren, Bo Niklasson

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The effects of LV in two different species, CD-1 mice, without a genetic disposition for diabetes, and BB rats prone to T1D were examined. Male CD-1 mice that had been exposed toLV in utero developed a type 2-like diabetes with increased blood glucose, insulin levels and epididymal fat at the age of 10-15 weeks. Combination therapy including LV-antiserum and an antiviral drug, Pleconaril, significantly reduced the levels of blood glucose and insulin and the amount of abdominal fat. In BB rats, LV has been found in both prediabetic- and diabetic diabetes-prone rats, as well as in diabetes-resistant rats. To evaluate whether the presence of LV has any influence on the onset of T1D, prediabetic BB rats were treated with an antiserum against LV or a combination of the antiviral drugs Pleconaril and Ribavirin. In the group treated with antiviral drugs, the onset was significantly delayed. These results indicate that the presence of LV can be involved in the pathogenesis of diabetes in these animal models.

Original languageEnglish (US)
Pages (from-to)567-572
Number of pages6
JournalMicrobiology and Immunology
Volume53
Issue number10
DOIs
StatePublished - Oct 1 2009

    Fingerprint

Keywords

  • Antibody treatment
  • Antiviral therapy
  • Viral infection

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology

Cite this